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Sammanfattning 
 
Introduktion: God följsamhet till antiretroviral behandling (ARV) av human 
immunodeficiency virus (HIV) är avgörande för en framgångsrik behandling. En 
gynnsam behandling ger HIV/AIDS patienten ökad livskvalitet och mindre risk för 
utvecklande av medicinsk resistans. Kamratstöd är en vedertagen metod som kan hjälpa 
patienten till en god följsamhet. För att nå framgång i behandlingen av HIV patienter är 
det ur ett folkhälso- policy perspektiv av stor vikt att studera de ekonomiska och sociala 
aspekter som inbegriper behandlingen och metoden kamratstöd. Syfte: Att undersöka 
om det fanns skillnader i följsamhet till antiretroviral behandling för patienter som fick 
kamratstöd och patienter som inte fick kamratstöd i DOTARV projektet i Quang Ninh, 
Vietnam. Syftet var att undersöka följsamhet till ARV i relation till kön och patienter 
med tidigare drogmissbruk. Metod: Data analyserades från den randomiserade 
kontrollerade studien DOTARV projektet. Projektets intervention var kamratstöd. En 
grupp av 641 patienter randomiserades till två olika behandlingskohorter; optimal 
kontrollerad behandling (OCR), som innebär att patienten får kamratstöd och själv 
bevakad behandling (SST), som innebär att patienten själv kontrollerar sin behandling 
utan kamratstöd. Kohorterna följdes upp under två år via självrapportering. En 
epidemiologisk och statistisk metod applicerades för att undersöka effekten av 
interventionen kamratstöd i relation till kön och tidigare drogmissbruk. Resultat: 
Frekvensen av icke-följsamhet bland män och kvinnor, tidigare drogmissbrukare och 
icke drogmissbrukare jämfördes, men gav inte några signifikanta skillnader mellan 
gruppen med kamratstöd och gruppen utan kamratstöd. Emellertid rapporterade tidigare 
drogmissbrukare och manliga patienter inom gruppen med kamratstöd en signifikant 
högre icke-följsamhet jämfört med patienter utan drogmissbruk och kvinnor. 
Regressionsanalysen visade på att gruppen med kamratstöd hade mindre association 
  
 
med icke-följsamhet än gruppen utan kamratstöd. Diskussion: Till skillnad från andra 
studier av följsamhet i antiretroviral behandling och kamratstöd i relation till kön och 
drogmissbruk visade resultaten inga signifikanta skillnader i följsamhet mellan 
patientgruppen med kamratstöd och patienter som tillhörde gruppen utan kamratstöd. 
Resultatet kan bero på att confounders i studien eller bias i själv 
rapporteringsmätningarna påverkat utfallet. Dock var det en signifikant association till 
icke- följsamhet för kamratstödgruppen jämfört med gruppen utan kamratstöd, som kan 
visa på att kamratstöd är associerat med följsamhet. Resultaten från denna studie kan 
skilja sig från de slutliga resultaten från DOTARV projektet, eftersom projektet 
fortfarande pågår.  
 
Sökord: HIV, Följsamhet, Antiretroviral behandling, Kamratstöd, Quang Ninh 
 
 
Abstract 
 
 
Introduction: Adherence to antiretroviral therapy for patients with human 
immunodeficiency virus (HIV) is important to obtain a successful treatment, increased 
quality of life and to decrease drug resistance development in patients. Peer-support is a 
well-known method, which can help HIV/AIDS patients to improve adherence. 
Moreover, to improve the therapy for patients living with HIV it is from a public health 
policy perspective important to study the economical and social benefits of adherence 
for the treatment and the method peer support. Aim/objective: To assess if there were 
differences in ART adherence among patients receiving peer support and those who do 
not in the DOTARV project in Quang Ninh, Vietnam. An additional aim is to 
investigate adherence in relation to sex and former drug use. Method: Data was 
extracted from the randomized controlled trial, the DOTARV project. The intervention 
of the project was peer support. A treatment cohort of 641 patients was randomized into 
two different treatment cohorts; optimally controlled treatment (OCR) receiving peer 
support, which means that patients get peer support and self-supervised treatment 
(SST), which means that patients controlled the treatment without help from a peer 
supporter. The cohorts were followed up during two years with self-report measures of 
adherence. An epidemiological and statistical method was applied to investigate the 
effect of the peer support intervention in relation to gender and IDU´s. Results: 
Comparison of frequencies for non-adherence among men and women, former injection 
drug users and patients without drug use, revealed no significant differences between 
the support group and the non-support group. However, drug users and male patients 
within the support group reported a significantly higher non-adherence than patients 
without a former drug use and women. The regression analysis showed that the support 
group had less association with non-adherence than the non-support group. Discussion: 
In contrast to former studies on ART adherence and peer support, the results showed no 
significant differences in adherence between the patients receiving peer support and the 
patients without support. This could be due to confounders in the study or bias in the 
self-report measurements. There was a significant association with non-adherence for 
the  support group compared to the non-support group, which could indicate that peer 
  
 
support is associated with adherence. The results from this study may differ from the 
final results of the DOTARV project, which has not ended yet. 
 
Keywords: HIV, Adherence, ART, Peer support, Quang Ninh 
  
 
Preface   
 
In the months of February 2010 to mid May 2010 we participated in an exchange 
program sponsored by Sida, between Gothenburg University and Hanoi Medical 
University in Hanoi, Vietnam. Part of the exchange program was to write our bachelor 
thesis in the context of Vietnam and with help from tutors related to Hanoi Medical 
University. For this thesis we had the unique opportunity to experience and investigate 
the randomized controlled trial; the DOTARV project, which takes place in the Quang 
Ninh province. We worked closely with the staff from DOTARV and received help and 
advice from the staff at Hanoi Medical University. It was a very challenging and 
educative period in which we learned a lot about Vietnamese work ethics, 
administration practices, and Vietnamese culture.  
 
We thank our tutor in Vietnam, Mattias Larsson for giving us access to the DOTARV 
data material. We would also like to extend a heartfelt thanks to DOTARV’s statistician 
Tran Thanh Do, for taking time to help us with the statistical calculations. Finally, 
we would like to thank our tutor in Sweden, Lena Andersson for constructive and 
helpful advice.  
 
  
 
List of Abbreviations 
 
AIDS- Acquired immunodeficiency syndrome 
ART- Antiretroviral treatment or therapy 
ARV- Antiretroviral 
DOTARV- Direct observed treatment antiretroviral treatment 
FSW- Female sex worker 
HAART- Highly active antiretroviral therapy 
HIV- Human immunodeficiency virus 
IDU- Intravenous drug user 
PEPFAR- The United States president's emergency plan for AIDS relief 
PLWHA- People living with HIV/AIDS 
RCT- Randomized controlled trial 
OCR- Optimally controlled treatment 
SST- Self-supervised treatment 
  
 
Conceptual explanations 
 
 
Adherence Here defined as following the physician’s guidelines for the 
prescribed drug regimen. 
CD4 count A test used to determine when a HIV patient should start 
treatment (Avert, 2010c) 
Combination therapy  Taking two or more antiretroviral drugs at a time. Reduces 
the rate of resistance (Avert, 2010b). 
First line therapies  Combination of drugs that a HIV patient is given in the 
initial treatment phase (Avert, 2010b). 
Opportunistic infections Infection caused by different pathogens that would usually 
not cause disease in a person with a healthy immune system, 
i.e. tuberculosis, fungal diseases etc. (Seeley, Stephens & 
Tate, 2008).  
Second line therapies  ARV drugs used when the patient has developed resistance 
to first line therapies, or if adverse side effects occur (Avert, 
2010b). 
Viral load The number of viral RNA molecules in a mL blood. High 
viral load can be an indicator of development of AIDS or 
viral resistance (Seeley, Stephens & Tate, 2008). 
Peer support  Is meant to be understood as: social support provided to a 
patient by a person with the same disease 
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1. Introduction 
 
For the first time since the discovery of human immunodeficiency virus (HIV)/ acquired 
immunodeficiency syndrome (AIDS) there are signs of progress and the HIV 
transmission rate is actually decreasing globally. Nevertheless, the HIV epidemic 
remains an urgent public health problem. In 2007 there were an estimated 33 million 
people living with HIV, the incidence was 2.7 million, and 2 million people died 
globally from AIDS (UNAIDS, 2008). About 300.000 people are living with HIV/AIDS 
in Vietnam, which is less than 1% of the overall population. However, the HIV 
epidemic in Vietnam is increasing as well as the need for treatment (WHO, 2009a). 
There are large geographical differences in HIV prevalence and the highest rate is found 
in the north, in the province of Quang Ninh. The highest concentration of HIV positive 
people is seen among intravenous drug users (IDU’s) (Thanh, Moland & Fylkesnes, 
2009). In Vietnam as a whole, the HIV epidemic is predominantly among IDU’s and 
female sex workers (FSW’s). The prevalence has reached 50-60% among IDU’s and 
16% among FSW’s in a number of provinces (WHO, 2005). This is a cause of grave 
concern because there is a high transmission risk from HIV infected IDU’s and FSW’s 
to the general population (Thanh et al., 2008).  
 
Antiretroviral therapy (ART) is well documented as an effective treatment for people 
living with HIV/AIDS (PLWHA). However, the effectiveness of the treatment is 
dependent on patient adherence (Paterson et al., 2000). Non-adherence to ART is a 
multi-factorial problem that includes patient, treatment and contextual factors (Remien, 
Hirky, Johnson, Weinhardt, Whitter & Minh Le, 2002). Studies have indicated that non-
adherence is associated with drug resistance, opportunistic infections and higher risk of 
developing AIDS (Bangsberg et al. 2003; Paterson et al., 2000). For low income 
countries like Vietnam, discovering ways to increase adherence in HIV/AIDS patients 
could be an important issue in relation to improving patient health, and being able to 
afford optimal treatment regimens for patients in the future.  
 
 
2. Background 
 
In Vietnam the HIV epidemic is concentrated to different areas as well as different 
groups of people, however the transmission risk is high at the moment and the need for 
treatment is increasing (Thanh, Moland & Fylkesnes, 2009; Thanh et al., 2008). At 
present only an estimated 30% of PLWHA receive treatment in Vietnam (WHO 2009b). 
The Vietnamese government has implemented several programs with health 
promotional aims to address the HIV/AIDS epidemic as a whole. As an example, the 
Prime Minister of Vietnam approved a National Strategy on HIV/AIDS in 2003 which 
adopted international practices on prevention, care, support and treatment of HIV/AIDS. 
The strategy also included harm reduction for drug users and sex workers (WHO, 
2005). Furthermore, the goal of the National Strategy of HIV/AIDS Prevention and 
Control in Vietnam has in recent years been to expand voluntary counseling and testing 
services in provinces and districts. Another goal has been to increase access to ART 
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through price reduction and local production of medicine. Moreover, the development 
of a comprehensive care, treatment and support system has been an objective (WHO, 
2005). The national guidelines recommend a first line combination Antiretroviral 
therapy consisting of the drugs Stavudine (or Zidovudine) together with Lamivudine 
and Nevirapine (or Efavirenz). This kind of therapy cost about US$ 260 per patient per 
year for a locally produced Vietnamese drug, and US$ 545 for a branded product 
approved by the World Health Organization (WHO). Branded drugs are more than 
twice as expensive as locally produced drugs. For a low-income county like Vietnam 
with a gross national income per capita of 2.310 purchasing-power-parity international 
dollars, the prices are not really affordable for patients without financial help. The gross 
national income per capita in Vietnam can be compared to Sweden that has 34.310 
purchasing-power-parity international dollars (WHO, 2010a, 2010b). The gross national 
income shows the average income by a country’s citizens. In recent years, the 
Vietnamese government has begun to distribute locally produced ARV drugs. 
Branded® ARV drugs have been distributed with the support from the United States 
President’s Emergency Plan for AIDS Relief (PEPFAR), and generic ARV medicine 
has been dispersed with support from Ensemble pour une Solidarité Thérapeutique 
Hospitalière En Réseau (ESTHER) and Global Fund to Fight AIDS, Tuberculosis and 
Malaria. These and other organisations provide support to Vietnam, working with the 
Vietnam Ministry of Health, bilateral organisations, United Nation agencies and non- 
governmental organizations (NGO’s) (WHO, 2005). These collaborations have been 
necessary to increase access to drugs for patients. In line with the national strategy, 
services for testing, and care and support for PLWHA are available in the national and 
provincial hospitals. However, the services are deemed poor in number and capacity 
(WHO, 2005). WHO estimates that effective interventions for harm reductions that 
reach vulnerable groups like FSW’s, or IDU’s should be implemented to a larger degree 
and be linked to health services (WHO, 2005). This paper will focus on HIV/AIDS 
patients in the context of Northern Vietnam, in the Quang Ninh province where the 
highest prevalence of PLWHA is seen, and the main risk group is IDU’s.  Furthermore, 
it will focus on ARV treatment of these patients, and the problems relating to this 
treatment.  
 
 
2.1 Antiretroviral treatment 
 
The use of combination antiretroviral therapy for the treatment of HIV patients and the 
use of primary prevention for opportunistic infections like tuberculosis or fungal 
infections have had a significant effect on the global HIV/AIDS epidemic (Moyle et al., 
2008). ART suppresses the viral load in patients and improves the strength of the 
immune system, thereby decreasing the amount of opportunistic infections and 
improving the quality of life for the patient (Moyle et al., 2008). Effective ART 
regimens have improved the prognosis of HIV patients (Moyle et al., 2008), and the 
disease is at present considered a chronic disease (Bartlett, 2002). HIV/AIDS patients 
have to take the treatment for the rest of their life and this can represent several 
problems. These include for example, the availability and financial costs of the 
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medicine, the treatment of side effects and the problem with patients not following the 
treatment guidelines.   
 
 
2.2 Cost and availability of antiretroviral treatment 
 
Generally, low-income countries have had difficulties in procuring life saving 
medications like ART because of excessive drug costs. Drug prices have been and are 
presently high due to long enduring drug patents and low price-competition on the drug 
markets. This condition is due to larger drug companies’ monopoly on medicines 
(Avert, 2010a). Recent expiry of patents on first line therapies for HIV and pressure on 
the larger drug companies by independent agencies, NGO’s and even governments to 
lower the price of ART drugs, have resulted in low income countries being able to 
procure low cost treatment for HIV patients. A positive development is that several drug 
companies in low-income countries have begun producing and distributing affordable 
ARV drugs (Avert, 2010a). In Vietnam, agencies like UNITAID, the Clinton 
Foundation and PEPFAR are providing increased coverage for HIV positive patients 
(Avert, 2010a; Castelli, Pietra, Diallo, Schumacher & Simpore, 2010). The positive 
developments in production and decreased prices for drugs are still mostly seen for first 
line drug therapies, and not for second line therapies, which are often newly developed 
drugs. Second line therapies are therefore often more expensive, because patents for 
new drugs will run for a longer period (Avert, 2010a). This is problematic because 
second line therapies can be more efficient and have fewer side effects (Avert, 2010a). 
Moreover, an increased demand for second line therapies could arise in the future, if 
resistance development to ARV increases in patients. A number of studies have shown 
that non-adherence is related to patient drug resistance development, development of 
opportunistic infections and admission to hospital (Bangsberg et al., 2003; Bartlett, 
2002; Moyle et al., 2008). The object of ARV treatment is to obtain sustained 
suppression of viral load, which requires adherence to more than 95% of treatment 
doses (Bartlett, 2002; Moyle et al., 2008; Visnegarwala, Rodriguez-Barradass, Graviss, 
Caprio, Nykyforchyn, & Laufman, 2006). Resistance development to ART limits the 
range of treatment options (Bartlett, 2002; Peltzer, Friend-du Preez, Ramlagan & 
Andersson, 2010). In relation to the expense of second line therapies, procuring 
treatment for HIV positive patients may become problematic with increased resistance. 
This is especially true for low-income countries like Vietnam that rely on international 
funding to obtain drug coverage for HIV/AIDS patients. In this respect it is important 
for Vietnam to discover cost-effective ways to improve adherence and integrate this in 
policies for national and local health promotional programs.    
 
 
2.3 Obstacles to adherence  
 
There can be many obstacles present for the patient regarding adherence to a medical 
regimen. Most studies that has investigated adherence, defines adherence as missing 
medication doses. However, non-adherence can also be not taking the medicine 
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correctly, i.e. at the wrong time, or not taking it with meals. It is often necessary to take 
ART at specific times and with meals, and to store the medication at specific 
temperatures (Bartlett, 2002; Moyle et al., 2008). These prescriptions can be an obstacle 
to the patient. Furthermore ART regimens often have quite a few side-effects such as 
vomiting, headache and diarrhea (Remien et al., 2002). Also, structural, biological, 
social, behavioral, demographic or economic reasons for non-adherence could be 
relevant issues for a patient (Silva et al., 2009). Several studies have investigated these 
and other possible reasons for non-adherence. For example, Silva et al. (2009) found 
variables like daily dose, use of alcohol or former drug use to be significantly associated 
with non-adherence to ART. They found no association between adherence and 
demographic variables like gender, age, marital status, educational level and sexual 
orientation. Another study has also shown worse adherence among active drug users 
and alcohol users (Wang et al., 2008). However, the relationship between gender and 
adherence to ART has not been properly established yet. Berg et al. (2004) showed that 
there are differences between men and women’s social and behavioral patterns that lead 
to different factors associated with adherence. In Vietnam, where the HIV epidemic is 
concentrated in vulnerable groups like IDU’s and FSW’s adherence should be 
investigated further to discover adherence patterns for these risk groups. This is 
important because improving adherence could require different strategies for different 
risk groups. One strategy that has proven to be feasible and effective in other contexts is 
the intervention of peer support. 
 
2.4 Improving adherence through peer support 
 
Understanding the adherence patterns and methods to meet high adherence in patients is 
a complex matter. Bartlett (2002) has suggested that to increase adherence, it is 
necessary to make an effort to motivate and educate the patient.  Peer support is a form 
of social support, which has been shown to affect adherence for patients. The 
intervention peer support as a part of HIV treatment has been used since the beginning 
of the HIV epidemic, and interventions based on peer support have been indicated to be 
feasible, practical, cost-effective and exportable (Simoni et al., 2007). One study 
conducted in South Africa, using self-report measures, found that social support showed 
higher adherence (Peltzer, Friend-du Preez, Ramlagan, & Andersson, 2010). Moreover, 
high adherence was found among people who received information about the treatment, 
and among people with high behavior skills. Peer support related to adherence and 
gender and drug use has also been investigated. One study, conducted by Visnegarwala 
et al. (2006), found a positive effect on adherence in women by weekly delivery of 
medications by a HIV positive peer supporter. Another study by Sharma et al. (2007) 
found that for former drug users not attending counseling about ART in the last six 
months influenced adherence negatively. In a study cohort of present and former opioid 
drug users, worse adherence was found in people that did not belong to a HIV support 
group and people with current use of crack or cocaine (Berg et al., 2004). Further, 
Remien et al. (2002) found that substance addiction is likely to influence adherence. 
The authors suggest that specialized support with clinical intervention can help patients 
with a history of substance use (Remien et al., 2002). 
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2.5 Health promotion and health policy  
 
Adherence improvements are important to the Vietnamese government, as well as for 
the sponsor organisations that it collaborates with and further for PLWHA. As 
explained earlier, resistance development in patients can create considerable financial 
problems as well as decrease patient health and well-being. In public health the 
perspective on health is multidimensional, meaning that health is not simply absence of 
disease. Health is seen as a resource that can be strengthened on societal level as well as 
the individual level (Andersson, 2006). A health promotional model that includes 
systematic preventive and promotional measures to improve health is often used 
(Janlert, 2000). In health promotion, the individual is given the tools and support to take 
command of their own life situation and the problems they are facing in everyday life 
(Andersson, 2006).  
 
In Vietnam, the government has implemented several national programs with preventive 
objectives, and instigated projects with international agencies targeting ART 
availability. Health policies and health promotional programs are therefore well used in 
Vietnam. In the field of health policy, epidemiological data is often used in health 
promotion planning (Ferraz- Nunes, Karlberg & Bergström, 2007). Taking an evidence-
based approach to policy making is important to have a sound foundation for decisions. 
What constitutes as evidence can be argued. An evidence based approach does not mean 
that one method has privilege over another or that there is only one hierarchy of 
evidence. Best evidence and best practice depends on the fitness for purpose and being 
able to explain choices (Kelly, Morgan, Bonnefoy, Butt & Bergman, 2007). A scientific 
basis for decision-making is unarguably a necessary approach to health promotion and 
preventive measure in the field of health policy. Health policy measures, as well as 
health promotional measures can be instigated at different levels of society, depending 
on the objective and target group. Using peer support with a health promotional 
objective would require a scientific basis indicating that this kind of intervention is 
feasible and effective. In behavioral science several theories have been developed to 
explain how social support affects the health of individuals, and where interventions 
containing social support should be instigated in society (Dahlgren & Whitehead, 2007).  
 
 
2.6 Peer support, sense of coherence and empowerment of patients 
 
Poor health such as living with HIV/AIDS, has many consequences for an individual. 
These are for example loss of earnings from employment, unemployment, social 
isolation or exclusion (Dahlgren & Whitehead, 2007). Stigmatization creates these 
forms of exclusions in society. In order to prevent such outcomes, empowerment and 
sense of coherence are important factors for a greater health. The purpose of 
empowerment at the individual level is to give the person possibilities to increase 
control over their life situation and to make decisions for themselves (Janlert, 2000). 
Different types of social networks, participation and supportive relationships have been 
indicated to have positive effect on a person’s health (Dahlgren & Whitehead, 2007). 
Visnegarwala et al. (2006) believed that peer support empowered women in their study, 
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which lead to greater adherence. Moreover, Bartlett (2002) suggests that patients need 
to understand the treatment and the effect of non-adherence on their health. He also 
believes that the patient should be given a motivational goal for the treatment. These 
strategies can all be said to give empowerment to the patients and they can be 
implemented in clinical settings; however, they can also be implemented via peer 
support. Overall such strategies will help empower the patients to understand their 
situation and make beneficial choices for themselves. In addition, peer support can 
increase the sense of coherence for HIV/AIDS patients. Sense of coherence includes 
understanding, coping and meaning in life (Janlert, 2000). Understanding means that the 
individual can understand and predict the signals of the surroundings and the body. 
Coping implies that an individual has the resources to meet the demands that the signals 
send, and meaning in life signifies that these demands are worth meeting for the 
individual (Janlert, 2000). Peer supporters can help the patient cope with their situation, 
understand their situation and find meaning in life by providing emotional, 
informational, instrumental, appraisal support (Uchino, 2004). Emotional support means 
that the peer supporter listens, cares and shows empathy towards the patient. 
Informational support implies that the peer supporter provide the patient with facts and 
guidelines. Instrumental support means help with day-to-day tasks and practical issues, 
such as remembering to take the medication. Finally, appraisal support suggests that the 
peer supporter acknowledges the patients efforts in a constructive way (Uchino, 2004). 
 
Figure 1. Conceptual framework of the impact of social networks on health 
 
                    Upstream factors                                           Downstream factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Adapted from Berkman, Glass, Brissette and Seeman (2000). 
 
Figure 1. depicts a conceptual framework of the impact of social networks on health. 
The positive and protective effects of peer support on the patients all occur at the micro-
level of the model, which can impact health through for example psychological 
pathways (Dahlgren & Whitehead, 2007). Dahlgren and Whitehead (2007) who have 
adapted the model believe that the model helps to suggest entry points for policy 
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measures from the macro- to the micro-level. Positive and protective effects on the 
psychosocial mechanisms can have an impact on health behavior pathways. Adherence 
is a health behavior and could as such be an outcome of positive or protective effects of 
peer support on psychosocial mechanisms. Peer support interventions happen at the 
micro-level, however it may affect the other levels, influencing both upstream factors 
and downstream factors. According to Dahlgren and Whitehead (2007) a successful 
intervention needs to consider both upstream and downstream factors as depicted in 
figure 1. Policies including action in both directions, for example; educations in the 
downstream to legislation in the upstream have been seen to be successful (Dahlgren 
&Whitehead, 2007). 
 
 
2.7 Gender inequalities in health 
 
That there are gender differences in health is a well-established fact. There are global 
gender inequalities in health as well as national, and the gap is increasing in low-income 
countries (Dahlgren & Whitehead, 2007). The inequalities between men and women 
should be seen from a social, cultural and economical perspective, as well as a 
biological perspective. Moreover, the social constructed inequalities should, if possible, 
be analyzed separately because the causes and size of the problem may differ between 
men and women (Dahlgren & Whitehead, 2007). In this way it is possible to investigate 
differences. Health promotion policies and sensitivity to gender issues in health are 
important in achieving optimal health with optimal measures (Doyal, 2001). When 
applying a gender perspective on the model, the different levels can be seen as being 
ingrained with socially constructed power distributions between the sexes. These power 
distributions manifests through gender disparities in the social networks and social ties 
of the individual, as well as the societal structure. The manifestations affect the 
psychosocial mechanisms of the individual, and thereby also the pathways. On 
understanding the gender inequalities ingrained at the different levels, the model could 
further be used to see health behavior from a gender perspective.   
 
 
2.8 Adherence and public health  
 
From a public health perspective, discovering effective measures of improving 
adherence is relevant not only to improve the health of HIV positive patients, but also to 
investigate if such interventions are practically and economically feasible in a low-
income country. As mentioned earlier, studies have shown promising results for peer 
support in improving adherence for ART. Peer support has even shown beneficial in 
improving adherence for gender and indeed even for former drug users. From a health 
economic perspective, improving adherence could lead to decreased hospitalization, 
increased productivity in patients and decreased need for second line therapies. 
Moreover, peer support is a cheap intervention option that could be cost effective 
(Simoni et al., 2007). Policies on increasing ART availability needs to consider 
adherence, and in relation to this also peer support. However, the effects of peer support 
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on adherence need to be studied further in contextualized settings, to serve as a basis for 
policymaking and health promotional program development. In light of this, the 
following objectives were developed for a randomized controlled trial (RCT) on the 
effects of peer support on adherence, in the Quang Ninh province of Vietnam where the 
HIV/AIDS epidemic is mainly concentrated among IDU’s.   
 
 
3. Aim/Objective 
  
To assess if there are differences in ART adherence among patients receiving peer 
support and those who do not in the DOTARV-project in Quang Ninh, Vietnam. An 
additional aim is to investigate adherence in relation to sex and former drug use.   
 
 
4. Method 
 
In the following, part of a data set from the Direct Observed Treatment of Antiretroviral 
Treatment (DOTARV) project was analyzed using epidemiological and statistical 
methods. The DOTARV project will be described in relation to the study design, the 
intervention and the data-collection methods. Lastly, the method of analysis for this 
paper will be presented, together with the ethical considerations of the study.  
 
 
4.1 Description of study  
  
The data for this analysis was made available from the DOTARV project, which is a 
randomized controlled trial (RCT) including 641 patients at present. The project was 
initiated in 2007 in the Quang Ninh province in Vietnam mainly because of the large 
HIV prevalence in this area. It is supported by PEPFAR, the Global Fund to Fight 
AIDS, Tuberculosis and Malaria and the Swedish International Development 
Cooperation Agency (Sida). The project is part of the collaborative efforts between 
these organisations and the Vietnamese government to improve access to ARV drugs in 
Vietnam. It has been running for two years and will continue for an estimated one and a 
half year more. The main aim of the project is to assess different ARV treatment 
strategies in the specific setting of Quang Ninh, Vietnam, and look at drug resistance 
and treatment failure. The different treatment strategies will eventually be evaluated and 
compared in relation to adherence of the patients, drug resistance development and 
treatment failure as a primary endpoint. In the following, the period considered will be 
from baseline and two years onwards (2007-2009). Thus the information mentioned 
from the project is preliminary and the final results from the trial may differ from the 
ones in this paper.  
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4.1.1 Inclusion criteria 
 
Inclusion criteria for patients in the DOTARV project were HIV positive patients aged 
18-59 years. The patients had to be clinically adequate for therapy based on CD4 count, 
and not be institutionalized elsewhere. Moreover, the patient should not have been 
treated with ARV drugs previously. The patient should not have developed tuberculosis 
when entering the project. The patient should have revealed his or her HIV status to a 
supporter and lastly a patient should be prepared to receive combination ART. 
 
 
4.1.2 Exclusion criteria 
 
People below 15 and above 60 years old were excluded in the study, as well as patients 
with current severe opportunistic infections, active tuberculoses, institutionalized 
patients and pregnant women.  
 
 
4.1.3 Study population 
 
The study population consisted of HIV/AIDS patients from the Quang Ninh province in 
Vietnam. The patients were randomized into two different treatment cohorts; optimally 
controlled treatment (OCR) through direct observation of the treatment, and self-
supervised treatment (SST) as recommended by the Vietnamese National AIDS Control 
Program. These treatment cohorts will hereafter be referred to as the support group and 
non-support group.  
 
 
4.1.4 Sample size  
 
A total of 641 patients were recruited from baseline and the patients entered the project 
at different points in time. There were a total of 332 patients in the intervention group 
and 309 patients in the non-support group that were recruited in the period from July 
2007 to December 2009. Eventually, 26 of the patients were arrested, 22 dropped out of 
the study and 54 died. Unfortunately, we have no information on whether the 
characteristics of the drop outs where different for the non-support group compared to 
the support group. Patients that had missed visits to the health centre were excluded 
from the analysis. The analysis was done on a study population of 606 patients, 
including both patients from the support and the non-support group. The exclusion of 
patients in the analysis resulted in data from 383 patients in the support group, and 223 
from the non-support group. Patients are recruited every month to the DOTARV 
project, which explains the increase of patients in the data used for analysis. In the 
support group there were 272 men and 111 women. Moreover, there were 166 
intravenous drug users out of the 383 patients in the support group. In the non-support 
group there were 149 men and 74 women and 128 IDU’s and 95 non- IDU’s. This 
means that there were a higher proportion of intravenous drug users in the non-support 
group, and that there were more men than women in both the support group and the 
non-support group.  
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4.1.5 Age distribution 
 
The age distribution was as follows; around 40% were between 18-29 years old.  A little 
over 50% were between 30-39 years old and the rest between 40-49 years old. A very 
little proportion was 50 years old or older.  
 
 
4.1.6 Socioeconomic and marital status  
 
A large proportion of the study population were temporary workers or unemployed. The 
rest were either drivers, in the service sector, miners, farmers, government officers or 
other. The education level of the study population was quite high with only 1% being 
illiterate. Around 40 % had finished secondary school and high school. Most people had 
finished secondary school and around 40% went to high school. A little under half of 
the study population were married, around 30% single and the rest either divorced or 
widowed. Almost half of the women were widowers and almost half of the men were 
single. There were no significant differences between the support group and the non-
support group regarding education, occupation and marital status. 
 
 
4.1.7 HIV transmission and intravenous drug use  
 
All the patients were asked about the route of HIV transmission at baseline. About half 
of the patients answered injection drug use and the other half answered through sexual 
intercourse. The patients were also asked about their history of heroin use. Around half 
of the study population had used heroin and the other half answered never. 70% of the 
men had a history of drug use. A little proportion of patients chose not to answer. When 
asked if they had used heroin in the last 6 months, around 20% answered in the 
affirmative.  There was no information from baseline about whether the female patients 
had been or where sex workers.  
 
 
4.1.8 Clinical condition of patients  
 
Most of the patients that entered the project had quite a low CD4 count and were 
therefore clinically adequate for therapy. In addition many of the patients had one or 
several opportunistic infections, due to a large part of them being in the later stages of 
HIV, where HIV is symptomatic, or when HIV has progressed to AIDS.  
 
 
4.2 Description of intervention 
 
Now that the inclusion criteria and characteristics of the study population have been 
described, we move on to the intervention itself. First and foremost, all DOTARV 
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patients received free combination ART and health checks on a monthly basis. The 
patients were required to pick up their medicine themselves at their assigned health 
centre every month. Moreover, all patients attended a health clinic at a quarterly basis to 
undergo a clinical examination, routine laboratory tests and have their well being 
assessed. At these visits, the health centre personnel performed adherence 
questionnaires. During the study period the patients were monitored for resistance 
development, or side effects of the medicine. If any adverse side-effects occurred, i.e. if 
the patient developed resistance or if the treatment did not show any effect, the 
treatment regimen was changed to attain optimal effect and well-being for the patient.  
 
 
4.2.1 Peer support to improve adherence  
 
The main intervention in the DOTARV project was the peer support intervention. This 
was what distinguished the support group and the non-support during the study. The 
Optimally Controlled Treatment (OCR) group, or the support group had weekly visits 
from a peer supporter, and the non-support group had no additional help, other than 
what they received at the health centre according to national guidelines on treatment of 
HIV patients. Peer supporters conducted weekly visits to the support group, and 
recorded changes in the patient’s condition or adherence to ART. Five to ten percent of 
the peer supporters’ recordings of information about the patients were controlled by a 
peer supporter supervisor every month. The supporter would ask the patient about side 
effects, count pills, and discuss barriers to taking ART and how to overcome these 
barriers. During the first two months, the supporter visited the HIV positive patient’s 
household or met the patient at an appointed place twice a week. Some patients 
preferred not to meet the supporter at their home because of fear of disclosure of their 
HIV status to their surroundings. Due to stigma the supporters did not have a work 
outfit. In this way, the supporters tried to minimize the patient’s fear of stigma from 
their surroundings. 
 
 
4.2.2 Selection and training of peer supporters   
 
At the outset, a total of 14 peer supporters were selected for the intervention. The 
supporters were all PLWHA, selected using the snowball effect method. This method 
entailed that the supporters asked friends, family or fellow patients that they found 
eligible to become a peer supporter. The supporters had to show good adherence to 
ART, have good communication skills, and have transportation opportunities like a 
motorbike or bicycle. The supporters were trained in peer support and educated about 
HIV/AIDS. They received basic information on HIV/AIDS, including transmission 
routes and opportunistic infections. Moreover, they received information about ART, 
the importance of adherence and the possible side effects of the therapy. The supporters 
also learned about stigma, how to perform patient visits and how to conduct the 
interviews in order to collect the data. In this way, the supporters were equipped to 
provide peer support to patients. Through the supporters’ own HIV status the level of 
understanding for the patient’s situation should theoretically be higher. The supporters 
had experience of the consequences of HIV themselves both regarding problems in the 
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social context relating to the stigma surrounding HIV, and the physical and emotional 
consequences of the disease. The training that the DOTARV project provided enabled 
the supporters to deal with occurrences of frustration, confusion, fear or other emotions 
that the HIV patient may have experienced during the study period. Additionally, the 
supporters gained information and support through participating in the DOTARV 
training, which could have helped them in coping with their own situation.  
 
 
4.2.3 Internal supporters  
 
The family or friends of the patient were included in the intervention as internal 
supporters. Internal meaning that they were in the internal part of the patient’s social 
network. Family members or friends acted as internal supporters in the daily life for the 
HIV positive patient. It was important that another person supervised every dose of 
ARV drug intake. The internal supporters helped the patient to remember to take the 
medicine and to answer questions about adherence at the peer support meetings. The 
peer supporters only visited the patient once a week and could not observe all dose 
intakes. Therefore a family member or another person close to the patient was supposed 
to observe all doses the patient needed to take during the study period. 
 
 
4.2.4 The non-support group 
  
In contrast, the patients in the self supervised treatment (SST) group, or non-support 
group, were responsible for their own treatment. However, they received treatment 
according to the National guidelines.  
 
 
4.3 How to collect data and measure adherence   
 
In the following the data collection and how to measure adherence in the DOTARV 
project will be described. 
 
 
4.3.1 Self-report measures on adherence  
 
The DOTARV project had several areas of data collection; assessment of adherence was 
one of them. There is no gold standard for measuring adherence, and several different 
strategies, i.e. pill counts, electronic monitors of pills, diaries and interviewer 
administered self-report questionnaires. Self-report measures can overestimate 
adherence, however this way of measuring adherence is inexpensive and is easy to 
distribute. In addition, self-report measures have been shown to be associated with HIV 
concentration in the blood (Chesney et al., 2000), meaning that low reported adherence 
has been shown to correlate with higher HIV concentration in the blood. For the 
DOTARV project, adherence assessment measures were developed using Adult Clinical 
Trials Group (AACTG) Adherence Instruments (Chesney et al., 2000). There are two 
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adherence questionnaires in this approach. The first is a baseline assessment of 
adherence, and the second is for follow up visits. The questionnaires were developed 
according to these, and carried out uniformly for both the support and non-support 
group. At baseline the patients were required to give consent to participation, and 
informed consent was ensured before data collection. Table 1. provides an overview of 
the data collection about information on adherence in the DOTARV project. 
 
 
Table 1. Types of data collection to investigate patients’ adherence to ART 
 
 
4.3.2 Pill counting to measure adherence   
 
Another adherence measure in the project was pill counting. All the patients in the two 
treatment cohorts were required to bring their pill bottles to the monthly visits to the 
health centers. The health staff counted remaining pills during these visits. In the 
support group, the supporter also counted pills during their visits.   
 
 
4.3.3 Data used for the analysis 
 
The data that were used in this analysis derived from the self-report measures only- i.e. 
the data came from the questionnaires about adherence that were distributed every third 
month by the health staff. These were chosen as the questions were posed uniformly for 
both the support and the non-support patient group and therefore were suitable for 
comparison between the treatment cohorts. Furthermore, the baseline information that 
was collected about the patient was used in the analysis.  
 
 
4.4 Method of analysis 
 
The statistical program SPSS version 16 was used to analyze the data. In corporation 
with the statistician at DOTARV the following methods of analysis were chosen to 
Data collection Time Collector 
Peer-supporter Questionnaires on; Baseline information, 
patient adherence, stigma, socioeconomic 
status, patient history, lab results, symptoms 
and quality of life. All self reported by patient
Before entering the 
project and use of 
ART 
 
& health staff 
  
Questionnaire on adherence to ART 
The first two months - 
twice a week, 
thereafter once a week Peer-supporter 
Health staff Questionnaire on adherence to ART and 
collection of information about side effects, 
lab results and symptoms Every third month   
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explore the data material in relation to the aims of this thesis. Frequency of non-
adherence was investigated in relation to the independent variables gender and former 
drug use. Moreover, nominal logistic regression analyses were performed to investigate 
associations between variables. For statistical significance Pearson’s Chi Square Test 
was performed for P-values. The DOTARV study design was that two study cohorts 
were followed from baseline and two years forward. For this reason it was possible to 
investigate causality, meaning whether peer support had an effect on self-reported 
adherence in the two different cohorts.  
  
4.4.1 Variables in the analysis  
 
Non-adherence was investigated in relation to the variables sex, former drug use and 
whether the patient was in the support or non-support group. The variables in the 
statistical analysis of the data were built by using the adherence information from the 
adherence questionnaires and the baseline data on the patients.  
 
 
4.4.2 The dependent variable  
 
Non-adherence was the dependent variable for the statistical analysis. Because of 
limited self-report data, the questions on adherence with the highest prevalence of 
answers were selected and later grouped. The patient was first informed: “The question 
below is about ART taken in the last four days”, thereafter the follow up questions 
displayed in table 2 were asked. The possible answers were categorized into the patient 
either having “adherence” or “non-adherence”. Following this, three groups were built 
for the coding of the data. These were: “adherence and not forgetting”, “non-adherence 
and forgetting” and “non-adherence or forgetting”. If the patient was categorized as 
adherent in the first and in the second question the patient was coded as adherent 
(Adherence and not forgetting). If a patient was categorized as non-adherent in the first 
question and non-adherent in the second question, the patient was coded as non- 
adherent (Non-adherence and forgetting). If a patient was categorized as non-adherent 
in the first question and adherent in the second question, the patient was coded as non-
adherent (non-adherence only or forgetting only). In this way the dependent variable: 
non- adherence was built.  
 
Table 2. Data coding on adherence and non-adherence from the adherence 
questionnaires 
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4.4.3 Independent variables  
 
The independent variables for the frequency analysis were sex and drug-use. 
Information about these variables was procured from the baseline questionnaire. 
Patients were asked about former drug use at baseline, and how they used drugs. If the 
patient had answered that they had used intravenous injection in the past, they were 
labeled as intravenous drug users (IDU’s) in the dataset. For the nominal regression 
analysis the independent variable, cohort, was additionally investigated, meaning the 
support group and the non-support group.  
 
 
4.5 Ethical considerations 
 
The international guidelines for ethical considerations regarding epidemiologic studies 
include; informed consent, confidentiality, benificience and nonmaleficience. 
Beneficience relates to an ethical obligation to maximize benefits for the participants, 
and nonmaleficience means that the study should not inflict harm on the participants 
(Andersson, 2006). Randomized controlled trials often carry more ethical problems 
compared to other study types (Andersson, 2006). For this study, randomization to the 
control group could mean that the patients were possibly reprieved of an effective 
means of increasing adherence, depending on the outcome of the study. However, for 
RCTs it is necessary to weigh up the advantages to the study outcomes, to the potential 
disadvantages for the control group. If the possible positive effect of the new kind of 
treatment or intervention measure is effective, this may benefit the larger patient group. 
For this study, no patient was deprived of the medicine itself, and the control group 
received the medicine according to the Vietnamese National Guidelines on treatment of 
HIV/AIDS patients. Additionally, all patients were treated for any opportunistic 
Questions Answers Category 
1 day 
2 days 
3 days 
4 days 
Non-adherence
 
How many days did you forget to take 
ARV in total? 
 
 
 
 Did not forget Adherence 
   
Total adherence Adherence 
Almost all the 
time 
Half of the time 
Some of the time 
What is your adherence level according to 
your doctor’s guidelines? 
 
 
 
 
 
No adherence 
Non-adherence
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infections that occurred. The peer supporters were all PLWHA and had to face their 
own disease as well as that of the patients they were visiting, giving many kinds of 
social support; emotional, instrumental, appraisal and informational. This called for a 
surplus of psychological strength on the supporters’ side and could have constituted a 
psychological burden for the supporters. Nevertheless, the meeting between patients 
with similar experiences could have increased a sense of coherence on both sides. There 
may possibly have been a two-way effect where the supporter also benefited from the 
exchange. Informed consent was obtained by informing the patients about what the self-
report measures was going to be used for, that all information given was confidential, 
and that the patient would remain anonymous. In this way, the patients were fully aware 
of the objectives of the study. HIV is a stigmatized disease in many societies around the 
world, and disclosure of HIV status to the surrounding environment can be a sensitive 
subject to a patient. This was also taken into account during the DOTARV project 
through the supporters not having a uniform or anything that would disclose to others, 
that they were affiliated with an HIV program. It was up to the patient to decide the 
place where they would meet with the supporter for the weekly meeting. Moreover, 
education about stigma was given to the peer supporters during their training.  
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5. Results 
 
The frequency of non-adherence was investigated in the patient cohort receiving peer 
support in relation to sex and former drug use. There was a significant difference in 
non-adherence between intravenous drug users (IDU’s) and non-drug users (non-
IDU’s). Intravenous drug users reported more non-adherence (31.3%) than patients 
without a former drug use (19.9%) (p=0.012, see table 3.). Moreover there was a 
significant difference in self- reported non-adherence between women and men. Men 
reported almost double as much non-adherence (30.9%) compared to women (15.3%) 
(p=0.002, see table 3.). The frequency of non-adherence was also investigated in the 
non-support regarding sex and former drug use. There were no significant differences in 
this group in self-reported non-adherence between men and women or intravenous drug 
users compared to non-drug users. To sum up, the only significant differences in non-
adherence were found in the support group, and these displayed higher non-adherence 
among intravenous drug users and to a certain extent among men. 
 
Table 3. Self reported non-adherence in patients receiving peer support among women 
and men, intravenous drug users (IDU’s) and non-drug users (non- IDU’s)  
 
Patients with peer support 
  
  
Male 
(n=), % 
Female 
(n=), % 
 
Total 
(n=), % 
p- 
value
IDU 
(n=), %
Non-
IDU 
(n=),% 
 
Total 
(n=),% 
p- 
value 
Non-
adher
ence  
 84 
(30.9%) 
 17 
(15.3%) 
 
 
101 
(26.4%)   
 68 
(31.3%)
 33 
(19.9%) 
 
 
101 
(26.4%)    
Adhe
rence 
188 
(69.1%) 
94 
(84.7%) 
 
 
282 
(73.6%)  
149 
(68.7%)
133 
(80,1%) 
 
 
282 
(73.6%)   
Total 
272 
(100%) 
111 
(100%) 
 
383 
(100%) 
* 
0.002
166 
(100%) 
217 
(100%) 
 
383 
(100%) 
* 
0.012 
 
* Comparison between frequencies  
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Table 4. Self reported non-adherence patients without peer support among women and 
men, Intravenous drug users (IDU’s) and non-drug users (non- IDU’s) 
 
Patients without peer support 
  
Male 
(n=), % 
Female 
(n=), %
 
Total 
(n=), %
p- 
value
IDU 
(n=),% 
Non-IDU 
(n=), % 
 
Total 
(n=), % 
p- 
value 
Non-
adhere
nce  
46 
(30.9%) 
18 
(24.3%)
 
64 
(28.7%)  
37 
(28.9%)
27 
(28.4%) 
 
64 
(28.7%)  
Adhere
nce 
 
103 
(69.1%) 
56 
(75.7%)
 
159 
(71.3%)  
91 
(71.1%)
68 
(71.6%) 
 
159 
(71.3%)  
Total 
149 
(100%) 
74 
(100%) 
 
 
223 
(100%) 
* 
0.309
128 
(100%) 
95 
(100%) 
 
 
223 
(100%) 
* 
0.937 
 
*Comparison between frequencies  
 
Because the object of interest was to assess differences in non-adherence between the 
support group and the non-support these groups were compared in relation to sex and 
former drug use. Women receiving peer support were compared with women not 
receiving peer support. There were no significant differences in self-reported non- 
adherence between the women (p=0.125, table 5). It was the same case for men 
receiving peer support and men not receiving peer support (p=0.998, table 5). 
 
Table 5. Comparison of non-adherence in women in support group with women in non-
support and between men in the support group and men in the non-support group 
  
 Female patients Male patients 
 
Non-
adherence 
(n=), % 
Adhere
nce 
(n=), %
Total 
(n=), %
P-
value
Non-
adherence
(n=), % 
Adhere
nce 
(n=), % 
Total 
(n=), %
P-
value
Non- 
support 
group 
18  
(24.3%) 
56  
(75.7%)
74 
(100%)  
46 
 (30.9%) 
103  
(69.1%) 
149 
(100%)  
Support 
group  
17 
(15.3%) 
94  
(84.7%)
111 
(100%)  
84  
(30.9%) 
188  
(69.1%) 
272 
(100%)  
Total 
35 
 (18.9%) 
150 
(81.1%)
185 
(100%)
* 
0.125
130  
(30.9%) 
291  
(69.1%) 
421 
(100%)
* 
0.998
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*Comparison of women with women, and men with men 
 
Furthermore, comparison of intravenous drug users in the support group with 
intravenous drug users in the non-support group did not reveal a significant difference 
in non-adherence (see table 6.).  
 
 
Table 6. Comparison of non-adherence between intravenous drug users (IDU’s) with 
patients without a drug use (non-IDU’s) 
 
 IDU’s Non- IDU’s 
 
Non- 
adherence 
(n=), % 
Adhere
nce 
(n=), % Total 
P-
value
Non-
adherence
(n=), % 
Adhere
nce 
(n=), % 
Total 
(n=), %
P-
value
Non-
support 
group 
37  
(28.9%) 
91  
(71.1%)
128 
(100%)  
27  
(28.4%) 
68  
(71.6%) 
95 
(100%)  
Support 
group 
68  
(31.3%) 
149 
(68.7%)
217 
(100%)  
33  
(19.9%) 
133  
(80.1%) 
166 
(100%)  
Total 
105  
(30.4%) 
240  
(69.6%) 
345  
(100%)
* 
0.636
60  
(19.2%) 
201 
(80.8%) 
261 
(100%)
* 
0.115
   
*Comparison of IDU’s with IDU’s, and non- IDU’s with non- IDU’s 
 
Table 7. displays the associations between non-adherence in the two groups. It was not 
possible to combine the questions to one variable of non-adherence, which meant that 
the variable non-adherence and forgetting had very small samples in each subgroup; 
male-female, support-non-support, IDU-non-IDU. This produced very large values for 
the confidence intervals as shown in table 7, and no significant values. Nevertheless, the 
variable where patients who had answered that they had been non-adherent or forgot, 
showed significant results. Male patients receiving peer support had more than double 
odds of reporting non-adherence in the support group compared to women (CI (1.02-
5.08), table 7). This concurs with the significant result within the support group where 
male patients reported more non-adherence than female patients. The patients in the 
support group had about half the odds of reporting non-adherence, compared to the 
patients not receiving peer support (CI (0.34-0.97), table 7). In plain words this means 
that receiving peer support was associated with reporting less non-adherence.  
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Table 7. Associations between non-adherence and cohort, gender and drug use. 
Associations presented as odds ratios (OR) with Confidence Intervals (CI).  
Odds ratio for non-adherence in the entire patient group 
  95% Confidence Interval  
Variables OR Lower Bound Upper Bound
Male 2.277 1.02 5.08 
Female  1 . . 
Support  0.572 0.34 0.97 
Non-support 1 . . 
IDU 1.539 0.76 3.12 
Non-
adherence 
only or 
forgetting 
only 
 
 
 
 
Non-IDU 1 . . 
Male 2.806 0.42 18.75 
Female 1 . . 
Support 1.446 0.55 3.84 
Non-support 1 . . 
IDU 0.509 0.12 2.14 
Non-
adherence and 
forgetting 
Non-IDU 1 . . 
 
 
 
  
 
21 
 
6. Discussion 
 
 
6.1 Discussion of method 
 
The DOTARV project is a randomized controlled trial with nearly 600 patients; 
however, self-report data on adherence were scarce, and is therefore seen as a weakness 
in the study. The method of the analysis is considered applicable according to the 
objective of this paper; to investigate differences in non-adherence in relation to gender 
and former drug use between the support group and the non-support group. Further, it 
was possible to sort the data in groups in order to analyze gender, IDU’s, non-IDU’s 
and compare the frequency of non-adherence in these groups according to the support 
group and the non-support group. It was not possible to perform a statistical analysis on 
the trend of the data, which is usually performed on longitudinal data. In addition, from 
a health policy perspective, a randomized controlled trial represents a sound evidence 
base from which to make policy. However as Kelly et al. (2007) argue, a randomized 
controlled trial does not mean that the best results will be found, or that it is 
automatically the best method. One needs to consider which method is best for the study 
question at hand. As an example, a qualitative study embedded within the trial could 
have been of use in order to investigate reasons for adherence among HIV positive 
patients in the DOTARV project.  
 
 
6.1.1 Strengths of the study  
 
The data from the DOTARV project is quite unique for Vietnam and there have been no 
similar trials on adherence before it. This can be seen as strength of the study. The 
sample size provided statistical power to the calculations, which strengthened the study 
results. The randomization reduced the chance of systematic bias in the study, as well as 
confounding factors (Andersson, 2006). The follow-ups on the patients throughout the 
study were a considerable strength of the study. There was a high amount of control and 
knowledge about the patient’s life situations as well as clinical situation, mainly through 
the peer supporter who recorded information about the patients every week. This 
information was further strengthened by checkups by the peer supporters’ supervisor. 
Also the health staff recorded considerable amounts of information about the health of 
the patient, and the baseline information about patient characteristics was extensive. The 
study was additionally strengthened by the DOTARV project’s several areas of data 
collection, meaning that adherence was investigated with different measures. First of all 
there were the self-report measures of adherence, which have proven effective in other 
studies, yet with a tendency to overestimation. There were not strong results of the 
effects of peer support from these measures; however, the trial has not ended yet. We 
may still see a difference in adherence in the support and non-support group measured 
via self-report. Furthermore, the viral load of the patients was checked, as well as the 
CD-4 count. These measures will help to see adherence patterns in the patients, and also 
it will be possible to correlate these results with the ones from the self-report measures. 
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Lastly, the drop out was low during the study period; 26 of the patients were arrested, 
22 dropped out of the study and 54 died. These low numbers can be considered strength 
of the study.  
 
 
6.1.2 Limitations of the study 
 
As mentioned earlier there was a certain amount of uncertainty in the adherence 
measurements, and there was not a lot of data on non-adherence from the self-report 
measures. As earlier mentioned self-report measures have a tendency to overestimate 
adherence. Moreover, self-report measures inherently carry a certain amount of 
response bias and recall bias from the patient. Moreover, the fact that the patient 
received expensive medications for free would have been an incentive to answer 
positively to questions on adherence. Fear of being denied further treatment plays a role 
here. Furthermore, counting pills is not an accurate measure of adherence because 
patients could have emptied their pill bottles before coming to the health centre, or 
where the support group is considered, before the arrival of the supporter. Patients could 
have done this for fear of not receiving new medicine, fear of disclosing non-adherence 
to the treatment regimen or other reasons. The pill counting in this respect should 
perhaps rather be seen as having been a mean for the supporter to help the patient 
remember the pills. For the health staff pill counting may have served as a reminder for 
the patient to remember to bring the pill bottle to the health centre. Finally, the data 
collection done by the health staff was not controlled, which could mean that there was 
bias in the collection.  
 
 
6.1.3 Validity, reliability in the study 
 
In the DOTARV project the validity and the reliability were controlled in several ways. 
Through randomization the variation was guaranteed in the study groups that were to be 
compared. Moreover, systematic and random errors were minimized with a longitudinal 
design, which also increases the possibility of stating causality (Andersson, 2006). 
When examining the quality of the study, except from confounders and random errors it 
is important to identify the validity and the reliability. Validity means how the method 
is constructed to measure what is meant to be measured. Validity includes both internal 
and external validity. Internal validity means thoroughness and external validity refers 
to the generalizability of the study results. Reliability means the dependability and 
precision of the study (Andersson, 2006). The data collection methods were developed 
according to former studies and guidelines. This means that the content validity was 
strengthened. Content validity signifies that an instrument measures what experts 
believe to be included in the concept that is to be measured (Andersson, 2006). 
Moreover, the use of peer support for improving adherence has been tested in earlier 
studies with positive results. This is a further strengthening of the internal validity. The 
reliability of the study can be questioned regarding the data collection done by the 
health personnel at the quarterly visits at the health centers. The questionnaires that 
were filled in by the nurses were not controlled like the supporters’ data collection was. 
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This means that there could be some bias in the data, if the data was not entered 
correctly, or if the health staff did not administer the self-report measure properly.  
 
6.1.4 External validity of the study  
 
The focus of the analysis was on intravenous drug users due to the high proportion of 
intravenous drug users in the area of Quang Ninh in Vietnam. The study results are 
highly contextualized to the setting that it was performed in. This means that it is not 
possible to generalize the results to all HIV /AIDS patients in other contexts. The results 
have relevance first and foremost for Vietnam and for the specific group of patients that 
the study included. Because the study population mainly consisted of intravenous drug 
users, the interpretation of the study results will have to relate to this fact. Nevertheless, 
intravenous drug use is the main HIV transmission route in Asia, and the results may 
have relevance for other areas where the HIV/AIDS epidemic is concentrated in this 
particular patient group.   
 
 
6.2 Discussion of results 
 
About 300.000 people are living with HIV/AIDS in Vietnam, which is less than 1% of 
the overall population. Nevertheless, the HIV epidemic in Vietnam is increasing as well 
as the need for treatment (WHO, 2009a). Adherence to antiretroviral therapy for HIV 
patients is essential to obtain a successful treatment. A successful treatment can increase 
a patient’s quality of life and decrease drug resistance development. In Vietnam the 
epidemic is predominantly among intravenous drug users and female sex workers. The 
government has instilled several measures to address the HIV epidemic, among other 
things to increase access to ARV treatment. To increase access will increase the need 
for interventions that will improve adherence in patients. Non-adherence to treatment 
can have detrimental effects on treatment effects and patient health. Moreover there is a 
risk of resistance development. The DOTARV project investigates peer support as a 
way of improving adherence to ARV treatment. The main findings of this thesis using 
data from the DOTARV project were that peer support did not show a particular 
improvement in self-reported adherence to antiretroviral treatment in relation to gender 
and former drug use. However, in the nominal regression analysis, male patients 
reported more non-adherence than female patients, and the support group had less odds 
of reporting non-adherence than the patients in the non-support group.  
 
 
6.2.1 Characteristics of the study sample and obstacles to adherence 
 
The study sample of the DOTARV project can be said to be representative for that 
particular region. However, the characteristics of that sample are probably transferable 
to other parts of Vietnam because the epidemic is spreading among former drug users 
and sex workers in all of the country. The patients from the Quang Ninh province were 
mainly former drug users and either temporary workers, unemployed or otherwise 
financially and socially speaking not in the upper layers of society. This represents 
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obstacles to adherence. As mentioned, former drug use has earlier been shown to have 
association to non-adherence (Silva et al., 2009). Taking medicine at specific times of 
the day can represent problems for patients that are working as for example truck 
drivers, or patients whose work routine changes within a short period like temporary 
workers. Moreover there are the side effects of the treatment, which can be quite severe 
(Remien et al., 2002), and represent problems for patients needing to adapt to new work 
situations. These obstacles to adherence would have been present for both the support 
group as well as the non-support group, and are important to take notice of.  
 
6.2.2 The support group and the non-support group  
 
Within the groups the only significant differences in self-reported non-adherence were 
found in the support group. Drug users reported more non-adherence compared to 
patients with no drug use. Remien et al. (2002) found that substance use is likely to 
influence adherence negatively, which correlates with our findings in the support group. 
Male patients receiving peer support reported significantly less adherence than female 
patients receiving support. This could relate to the fact that the main part of the 
intravenous drug users in the study cohorts was male. Drug users report reported more 
non-adherence and drug users were more often men in the sample. This could be a 
reason to why male patients reported more non-adherence. As earlier mentioned the 
relationship between gender and adherence has not been properly established yet, but 
drug use has been shown to be associated with non-adherence. For example, Silva et al. 
(2009) found that former drug use was significantly associated with non-adherence to 
ART. Nevertheless, the non-support group did not show significant differences in non-
adherence for neither drug users nor male patients. Whether peer support produced 
these differences in non-adherence within the support group is hard to establish. This 
was why the peer support group and the non-support group were compared.  
 
 
6.2.3 Sex, peer support and non-adherence  
 
Visnegarwala et al. (2006) found self-reported adherence improvements for women 
receiving peer support compared to women receiving standard care. Contrary to their 
findings, the results in this thesis showed no differences in self-reported adherence 
between female patients receiving support and female patients that did not. There were 
no differences among the male patients either. However, Silva et al. (2009) also found 
that sex is not a factor for non-adherence, which correlated with our results. In relation 
to this, it should be mentioned that the DOTARV project has not yet finished and the 
final end results may differ from our results. Furthermore, there is a large amount of 
HIV/AIDS interventions by other non-governmental organizations in the Quang Ninh 
province. As an example the organisation Pact has several ongoing interventions. One 
of these interventions is cooperation between CARE, PEPFAR and Global Fund and 
targets community health based care and support for HIV/AIDS patients. This means 
that there were other interventions working in different ways to improve the situation 
for PLWHA during the study period. The patients not receiving peer support in the 
DOTARV project could easily have been a member of these groups or partaken in 
networks related to them. This would have been a bias of the study, because the non-
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support patients would have received support through these other groups, which could 
have affected adherence. However, it would have been very difficult to control for this 
bias. Furthermore, the samples were small in the different subgroups, and a larger 
sample may have revealed different results. To sum up, peer support did not seem to 
have an effect on self-reported adherence in relation to sex. The reasons for this could 
be that peer support simply has no differentiated effect on non-adherence and sex, that 
confounding factors in the surroundings of the patients influenced the results or that the 
study has not ended yet, and the end results will differ. Moreover, there is the question 
of self-report as data collection method, which was discussed earlier.  
 
The results can also be seen in relation to health policy and the Berkman Glass, 
Brissette and Seeman (2000) framework described earlier. From a gender perspective 
the framework of social networks on health is ingrained with gender inequities. The 
framework shows that policies have impacts on different levels, and therefore also on 
the different inequities on the different levels. The peer support intervention was done 
on the micro-level, which is the individual level. Because the results did not produce 
any differences in self-reported adherence according to sex, one cannot say from this 
study that there is a need to direct peer support interventions differently to address 
gender differences in non-adherence. Policies addressing gender disparities in health are 
nevertheless important, which is why it was important to investigate sex and non-
adherence in relation to peer support.  
 
 
6.2.4 Intravenous drug users  
 
Berg et al. (2004) and Sharma et al. (2007) found that peer support influenced 
adherence positively among former drug users. Our results showed no particular 
difference in adherence between former drug users receiving support, and those who did 
not. Within the peer support group former drug users had higher non-adherence than 
non-drug users. From these results it is not possible to say that peer support has a 
beneficial effect on self-reported adherence in former drug users. Nevertheless, there 
may be further beneficial effects that peer support can achieve in patients that are not 
dealt with in this paper. These effects could be an increased quality of life, increased 
sense of coherence and empowerment of the patient. Both patients with former drug use 
as well as patients without could achieve these effects from peer support.  
 
 
6.2.5 The results from the nominal regression analysis  
 
In the regression analysis, male patients reported significantly more non-adherence than 
female patients, and the support group had significantly less association with non-
adherence than the patients in the non-support group. This result concurs with earlier 
studies on the effect of peer support on adherence, where peer support was shown to 
have a positive effect on adherence in patients (Berg et al., 2004; Peltzer, Friend-du 
Preez, Ramlagan, & Andersson, 2010). That there were differences in adherence for the 
support group is a quite positive result for peer support as an intervention option to 
improve adherence in patients. The results could indicate that peer support is a viable 
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intervention option. However, again it should be taken into consideration that the 
DOTARV project will continue for one and a half years more, and that the final result 
could be different from the results of this thesis. Moreover, the results from the 
frequency analysis showed that there was no difference in adherence between men and 
women, and former drug users and patients with no former drug use could indicate that 
these particular subgroups does not benefit especially from peer support. However, as 
there were confounders in the study, and perhaps overestimation of adherence from the 
self-report measures, this is hard to establish with any certainty.  
 
 
6.2.6 Health policy options for Vietnam  
 
Expiring patents have enabled several low-income countries, among them Vietnam, to 
produce and distribute ARV medication. Vietnam still relies on funding from outside 
parties to be able to supply HIV patients with branded and generic drugs. It is not likely 
that Vietnam will be able to afford the more newly produced medications in the near 
future when looking at their current status as a low-income country. In all probability 
focus on decreasing resistance development in patients will become increasingly 
important because Vietnam is now able to produce the first line therapies and distribute 
these to a larger degree. More patients will therefore have the probability of resistance 
development, and therefore also the need for second line therapies. Instilling policies at 
the micro-level in the Berkman, Glass, Brissette and Seeman (2000) framework, is 
another step for the Vietnamese government, because it has already made policies at the 
macro-level to improve access to treatment. Dahlgren and Whitehead (2007) said that 
policies including action in both directions have been seen to be successful. Including 
an intervention at the micro-level may therefore be just what is needed to obtain the 
goal of improving access. If patients develop less drug resistance due to less non-
adherence, then there will be less need for more expensive second line therapies. 
However, this is of course only an assumption.  
 
Peer support could be a health policy option for the Vietnamese government to reach its 
goal of increasing access to ART for HIV patients and obtaining harm reduction for 
intravenous drug users and female sex workers. Other studies have shown beneficial 
effects and peer support has been shown to be cost-effective, feasible, practical and 
exportable (Simoni et al., 2007). These aspects of peer support in the context of 
Vietnam, however, need to be further explored, before peer support is chosen as an 
intervention option. Moreover, the presence of other projects in the Quang Ninh 
province may have affected the results to a significant degree, as mentioned earlier. The 
DOTARV projects measures adherence via viral load in patients as well, and this data 
may also reveal a different result from the self-report measures. There are furthermore 
the beneficial effects of increased quality of life, sense of coherence and empowerment 
to be taken into consideration. Stigma reduction could be a further benefit of peer 
support, and this needs to be studied further in the Vietnamese context, and in relation 
to gender and drug use. Health policies should consider the intervention in light of these 
positive health effects as well. This is especially the case for a province like Quang 
Ninh, where the HIV infected population is mainly intravenous drug users and female 
sex workers. Targeting marginalized HIV infected subpopulations with an intervention 
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that could improve the general quality of life and reduce stigma would be in line with a 
public health perspective. Non-adherence creating resistance development in patients 
could increase the financial burden of providing patients with treatment.  
 
 
6.3 Suggestions for further research 
 
Additional research is needed to investigate HIV positive people’s adherence to 
antiretroviral treatment and how the adherence to the treatment can be improved. A 
qualitative study on the effects of peer support on the quality of life status of the 
patients is already being conducted in the DOTARV project. A further qualitative study 
could focus on the four different forms of social support; emotional, informational, 
instrumental and appraisal support which Uchino (2004) mentions as the four forms of 
social support. Such a study could examine which kinds of support the patients 
appreciate the most, and which forms of support that contributes the most to improving 
adherence. A qualitative study on the knowledge and attitude of the patients towards 
adherence to ARV treatment could reveal reasons for a patient not being adherent. Also, 
a study on stigma related obstacles to adherence in the Vietnamese context would be of 
use to see how peer supporters should address these issues. Furthermore, a cost-
effectiveness analysis is crucial when developing global, national and local policies for 
HIV prevention and care. Peer support may be an implementation option for IDU’s 
specifically, which national and local policymakers in Vietnam need to take into 
consideration. More knowledge is needed on the cost-effectiveness of peer support in 
the contextualized settings that the trial was carried out in, and the applicability to 
national policies.  
 
 
7. Conclusion 
 
Within the peer support group there was a significant difference between men and 
women and between former drug users and patients with no former drug use. In the 
regression analysis, male patients had a larger association with non-adherence than 
female patients, and the support group had less odds of reporting non-adherence than 
the patients in the non-support group. There were however, some confounders that 
could have disrupted the results, like other interventions in the study area that could 
have meant higher adherence in the non-support group caused by support form a 
different source than the DOTARV project.  Moreover, there could have been collection 
bias as well as recall bias in the self-report data. When the DOTARV project ends in 
one and a half years time, the results could differ from the ones in this paper. Finally, 
there were other measurements in the project that may reveal different results on 
adherence levels in patients. From a public health perspective, peer support as an 
intervention could be a policy option that the Vietnamese government should consider 
in reaching their goal of providing more patients with antiretroviral treatment.  
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